Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

Additional drug combinations may carry a risk of more side effects though, raising concerns from some doctors. Regeneron ...